US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 6.860
- +1.080+18.69%
Close Nov 29 13:00 ET
- 6.890
- +0.030+0.43%
Post 17:01 ET
374.73MMarket Cap10.39P/E (TTM)
7.030High6.266Low1.19MVolume6.270Open5.780Pre Close8.06MTurnover2.65%Turnover Ratio2.31P/E (Static)54.63MShares11.72052wk High1.13P/B308.04MFloat Cap5.19052wk Low--Dividend TTM44.90MShs Float31.910Historical High--Div YieldTTM13.22%Amplitude2.460Historical Low6.775Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Voyager Therapeutics Stock Forum
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
No comment yet